Literature DB >> 26835284

Minimal residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology?

Adriano Venditti1, Maria Ilaria Del Principe1, Luca Maurillo1, Francesco Buccisano1, Sergio Amadori1.   

Abstract

Entities:  

Year:  2013        PMID： 26835284      PMCID： PMC4728949          DOI： 10.3978/j.issn.2224-4336.2012.10.01

Source DB:  PubMed          Journal:  Transl Pediatr        ISSN： 2224-4336


× No keyword cloud information.
  11 in total

1.  Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.

Authors:  Andrea Corbacioglu; Claudia Scholl; Richard F Schlenk; Karina Eiwen; Juan Du; Lars Bullinger; Stefan Fröhling; Peter Reimer; Mathias Rummel; Hans-Günter Derigs; David Nachbaur; Jürgen Krauter; Arnold Ganser; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

Review 2.  Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.

Authors:  Francesco Buccisano; Luca Maurillo; Maria Ilaria Del Principe; Giovanni Del Poeta; Giuseppe Sconocchia; Francesco Lo-Coco; William Arcese; Sergio Amadori; Adriano Venditti
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

3.  Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia.

Authors:  Francesco Buccisano; Luca Maurillo; Alessandra Spagnoli; Maria Ilaria Del Principe; Daniela Fraboni; Paola Panetta; Tiziana Ottone; Maria Irno Consalvo; Serena Lavorgna; Pietro Bulian; Emanuele Ammatuna; Daniela F Angelini; Adamo Diamantini; Selenia Campagna; Licia Ottaviani; Chiara Sarlo; Valter Gattei; Giovanni Del Poeta; William Arcese; Sergio Amadori; Francesco Lo Coco; Adriano Venditti
Journal:  Blood       Date:  2010-06-14       Impact factor: 22.113

4.  Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.

Authors:  John A Liu Yin; Michelle A O'Brien; Robert K Hills; Sarah B Daly; Keith Wheatley; Alan K Burnett
Journal:  Blood       Date:  2012-08-08       Impact factor: 22.113

5.  Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.

Authors:  Hiroto Inaba; Elaine Coustan-Smith; Xueyuan Cao; Stanley B Pounds; Sheila A Shurtleff; Kathleen Y Wang; Susana C Raimondi; Mihaela Onciu; Jeffrey Jacobsen; Raul C Ribeiro; Gary V Dahl; W Paul Bowman; Jeffrey W Taub; Barbara Degar; Wing Leung; James R Downing; Ching-Hon Pui; Jeffrey E Rubnitz; Dario Campana
Journal:  J Clin Oncol       Date:  2012-09-10       Impact factor: 44.544

6.  Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.

Authors:  Wolfgang Kern; Daniela Voskova; Claudia Schoch; Wolfgang Hiddemann; Susanne Schnittger; Torsten Haferlach
Journal:  Blood       Date:  2004-07-29       Impact factor: 22.113

7.  Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

Authors:  Daniela Cilloni; Aline Renneville; Fabienne Hermitte; Robert K Hills; Sarah Daly; Jelena V Jovanovic; Enrico Gottardi; Milena Fava; Susanne Schnittger; Tamara Weiss; Barbara Izzo; Josep Nomdedeu; Adrian van der Heijden; Bert A van der Reijden; Joop H Jansen; Vincent H J van der Velden; Hans Ommen; Claude Preudhomme; Giuseppe Saglio; David Grimwade
Journal:  J Clin Oncol       Date:  2009-09-14       Impact factor: 44.544

8.  Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.

Authors:  Luca Maurillo; Francesco Buccisano; Maria Ilaria Del Principe; Giovanni Del Poeta; Alessandra Spagnoli; Paola Panetta; Emanuele Ammatuna; Benedetta Neri; Licia Ottaviani; Chiara Sarlo; Daniela Venditti; Micol Quaresima; Raffaella Cerretti; Manuela Rizzo; Paolo de Fabritiis; Francesco Lo Coco; William Arcese; Sergio Amadori; Adriano Venditti
Journal:  J Clin Oncol       Date:  2008-07-07       Impact factor: 44.544

9.  Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

Authors:  Susanne Schnittger; Wolfgang Kern; Claudia Tschulik; Tamara Weiss; Frank Dicker; Brunangelo Falini; Claudia Haferlach; Torsten Haferlach
Journal:  Blood       Date:  2009-07-08       Impact factor: 22.113

10.  The incidence and clinical significance of nucleophosmin mutations in childhood AML.

Authors:  Patrick Brown; Emily McIntyre; Rachel Rau; Soheil Meshinchi; Norman Lacayo; Gary Dahl; Todd A Alonzo; Myron Chang; Robert J Arceci; Donald Small
Journal:  Blood       Date:  2007-04-17       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.